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Abstract: Cumulative studies have provided controversial evidence for the prognostic values of 
bone morphogenetic protein 5 (BMP5) in different types of cancers such as colon, breast, lung, 
bladder, and ovarian cancer. To address the inconsistent correlation of BMP5 expression with 
patient survival and molecular function of BMP5 in relation to cancer progression, we performed a 
systematic study to determine whether BMP5 could be used as a prognostic marker in human 
cancers. BMP5 expression and prognostic values were assessed using different bioinformatics tools 
such as ONCOMINE, GENT, TCGA, GEPIA, UALCAN, PrognoScan, PROGgene V2 server, and 
Kaplan–Meier Plotter. In addition, we used cBioPortal database for the identification and analysis 
of BMP5 mutations, copy number alterations, altered expression, and protein–protein interaction 
(PPI). We found that BMP5 is frequently down-regulated in our queried cancer types. Use of 
prognostic analysis showed negative association of BMP5 down-regulation with four types of 
cancer except for ovarian cancer. The highest mutation was found in the R321*/Q amino acid of 
BMP5 corresponding to colorectal and breast cancer whereas the alteration frequency was higher in 
lung squamous carcinoma datasets (>4%). In PPI analysis, we found 31 protein partners of BMP5, 
among which 11 showed significant co-expression (p-value < 0.001, log odds ratio > 1). Pathway 
analysis of differentially co-expressed genes with BMP5 in breast, lung, colon, bladder and ovarian 
cancers revealed the BMP5-correlated pathways. Collectively, this data-driven study demonstrates 
the correlation of BMP5 expression with patient survival and identifies the involvement of BMP5 
pathways that may serve as targets of a novel biomarker for various types of cancers in human. 
Keywords: BMP5; BMP5 mutations; cancer prognostic biomarkers; cancer progression; multi-omics 
analysis; protein–protein interaction; bioinformatics 
 
1. Introduction 
Cancer is one of the leading causes of premature death [1,2]. According to the Cancer Statistics 
for 2019, the number of new cancer cases yearly in the United States alone for all sites combined was 
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1,762,450 with an estimated death totaled 606,880 [3]. Furthermore, the number of cancer patient is 
increasing due to population and aging [2]. One of the most dominant causes of oncogenesis is the 
accumulation of gene alterations which has a positive correlation to the prognosis of cancer patients. 
Cancer can be detected early by using diagnostic cancer markers that identify differentially expressed 
genes associated with the survival of cancer patients. Moreover, these diagnostic biomarkers can be 
exploited as therapeutic agents by successfully understanding their mechanism of alteration. 
Bone morphogenetic protein 5 (BMP5) is a member of the transforming growth factor-β (TGF-β 
) superfamily of signaling cytokines [4], which is located on the chromosome 2 in mice chromosome 
20 in humans [5]. It acts through either autocrine or paracrine mechanism by binding to cell surface 
receptors and initiate a sequence of downstream events that have effects on various cell types. BMP5 
is known for their ability to induce bone and cartilage development, differentiate osteoprogenitor 
mesenchymal cells and up-regulation of osteoblastic features by their direct and indirect influence 
over cytokines and growth factors [6]. Mutation in BMP5 is associated with a wide range of skeletal 
defects such as reduction in the long bone width and the size of the vertebral processes as well as the 
reduction of lower body mass [7,8]. It has been reported that BMP, together with its subtype BMP5, 
is involved in the initiation of several types of cancers such as colon, lung, breast, bladder, and 
ovarian cancer [9–16]. Previous studies on colorectal cancer showed a significant correlation between 
BMP5 down-expression and mutation and the prognostic value of colorectal cancer (CRC), triggering 
the initiation and development of tumors [12,14,15]. One study reported that 13 cases of BMP5 
mutation across seven cancers where gastrointestinal cancers (GICs) were the most influenced by 
recurrent hotspot mutations [13]. Likewise down-regulation of BMP5 has also been reported in other 
types of cancer such as adrenocortical carcinoma [9]. In contrast, the over-expression of BMP5 was 
observed in lung adenocarcinoma (LUAD) [13,17], and breast cancer [18,19]. However, later studies 
showed a positive correlation of BMP5 down-regulation with lower relapse-free survival in breast 
cancer patients and can be used as a therapeutic strategy combined with TGFβ1 to reduce cellular 
proliferation [20,21]. Down-regulation of BMP5 has also been reported in 6 out of 10 lung squamous 
cell carcinomas (LUSC) [22]. These findings suggest that BMP5 has an essential role in various cancer 
progressions. 
To study the expression and evaluation of BMP5 as a potential prognostic value for the treatment 
of various cancers, we systematically analyzed the BMP5 expression and its clinical outcomes in 
certain cancers. Numerous expression and patient survival datasets were used, which are available 
on various recognized online platforms. We also investigated the genes co-altered with BMP5 in 
relation to the five cancer types with high BMP5 expression. Therefore, these systemic analyses 
eventually determine whether BMP5 expression can be used as a biomarker for the prognosis of 
human cancer. 
2. Materials and Methods 
2.1. Analysis of mRNA Expression Levels in Different Cancers 
Analysis of mRNA expression was carried our using ONCOMINE 
(https://www.ONCOMINE.org/resource/login.html) [23,24]. The threshold for analyzing this gene 
was as follows; p-value: 1 × 10−4, fold change: 2, gene ranking: 10%; analysis type: cancer vs. normal, 
and data type: mRNA. The parameters were kept the same for all cancer types. 
2.2. Exploration of Gene Expression Pattern in Different Cancers 
Gene expression across normal and tumor tissue (GENT) (http://gent2.appex.kr/gent2/) is a web-
accessible resource where gene expression patterns between diverse human cancer and normal 
tissues are explored [25]. To obtain differential expression patterns of BMP5 in normal vs. cancer 
tissues, we used a set of default parameter on data sets, samples, and probes. 
2.3. Extensive Analysis of Gene Expression Data 
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UALCAN (http://ualcan.path.uab.edu) is a publicly available web tool to perform in-depth 
analyses of TCGA gene expression data [26]. It can analyze gene expression, promoter methylation, 
correlation, and prognosis. Using UALCAN database, we analyzed the expression pattern of BMP5 
mRNA. 
2.4. Exploration of RNA Sequence Expression in Different Cancer 
The gene expression profiling interactive analysis (GEPIA) is another interactive online platform 
that can explore RNA sequence expression between normal and cancer samples from TCGA and 
GTEx project [27]. We utilized GEPIA (http://gepia.cancer-pku.cn/) for differential expression 
analysis of BMP5 in tumor vs normal tissue from various cancers. It can also perform other functional 
analysis, including patient survival and correlation analyses. KM-Express (http://ec2-52-201-246-
161.compute-1.amazonaws.com/kmexpress/index.php) a platform known for identification and 
functional characterization of novel RNA biomarkers and targets in cancer survival and gene 
expression was used as well for this study [28]. 
2.5. Determination of Potential Cancer Biomarkers 
PrognoScan (http://dna00.bio.kyutech.ac.jp/PrognoScan/) is an online resource that was used to 
determine potential tumor biomarkers and therapeutic targets [29]. This platform has an extensive 
collection of cancer microarray datasets to assess the relationship between gene expression and 
patient prognosis. The parameter was adjusted to a Cox p < 0.05. 
2.6. Survival Analysis by PROGgene V2 Database 
PROGgeneV2 (http://watson.compbio.iupui.edu/chirayu/proggene/database/?url=progge) is a 
web-based platform that used to study prognostic implications of genes in different types cancer [30]. 
We applied PROGgeneV2 to perform survival analysis on BMP5 as a signature in various human 
cancers. The threshold was p < 0.05.  
2.7. Identification of Expression, Mutation, and Functional Protein Partners 
The cBioPortal for Cancer Genomics (http://cbioportal.org) is a widely used web platform for 
exploring, visualizing, and analyzing multidimensional cancer genomics datasets [31,32]. It contains 
various types of data, including mRNA expression, DNA copy number, DNA methylation, non-
synonymous mutations, and limited de-identified clinical data. cBioPortal was applied to explore 
expression, mutations, and CNAs of BMP5 with defined parameter settings in this study. Besides, 
the OncoPrint sub-tool of cBioPortal was also utilized to analyze the integrated status of mutations 
and CNAs for BMP5 and their functional protein partners. 
2.8. Analysis of Protein–Protein Interaction 
We used both the GeneMANIA and STRING servers for the protein–protein interaction analysis. 
Herein, GeneMANIA (https://genemania.org/) is an online interface used for generating hypotheses 
about gene function, analyzing gene lists and prioritizing genes for functional assays [33]. It is an 
extensive database of functional association data, including protein and gene interactions, pathways, 
and co-expression. We applied this database to predict the protein–protein interactions using BMP5 
as queries. The interactions between genes are displayed in the form of a network where nodes 
symbolize genes and links represent networks. STRING (https://string-db.org/) is another web-based 
data mining platform dedicated to protein–protein interactions, both physical and functional 
associations [34]. We used this database to determine the functional protein partners of BMP5. Several 
factors, including text mining, experiments, databases, neighborhood, gene fusion, and co-
expression, were considered as active protein–protein interaction sources. 
2.9. Finding Co-Expressed Genes of BMP5 and Its Pathway Analysis 
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Positively and negatively co-expressed genes of BMP5 were explored in TCGA dataset of five 
different types of cancer (breast, colon, lung, bladder and ovarian), using the R2: Genomics Analysis 
and Visualization Platform version 3.2.0 (https://hgserver1.amc.nl/), with the adjustment of 
Bonferroni test and cutoff p-value was selected as < 0.01. Thereafter, the common gene set was 
explored by drawing Venn diagrams, using co-expressed genes from five different cancers. 
To explore pathways and gene ontology shared by BMP5-correlated genes, we used Protein 
Analysis Through Evolutionary Relationships (PANTHER) tool (http://pantherdb.org/) [35] and 
GOnet: Gene Ontology Analysis (https://tools.dice-database.org/GOnet/) [36]. subsequently 
classified them based on their KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway (p < 0.05). 
2.10. Statistical Analysis 
Bar and forest plots were drawn using GraphPad Prism version 6 (GraphPad Software, La Jolla, 
CA, USA). All results are displayed with p-values obtained from a log-rank test (Supplementary 
Tables S2 and S3). R (version 3.6.1) programming language was used for custom scripts. Custom 
scripts based on pheatmap function as available in the ‘gplots’ Bioconductor project 
(http://www.bioconductor.org/) was used for hierarchical clustering and heatmaps. The fold-change 
of gene expression for heatmap were obtained from ONCOMINE database (Supplementary Table 
S4). 
3. Results 
3.1. BMP5 mRNA Expression in Various Types of Cancer 
We utilized databases such as ONCOMINE, GENT, The Cancer Genome Atlas (TCGA) through 
UALCAN, GEPIA, and KM-Express to investigate the differential expression pattern of BMP5 in 
various cancer types and their counterparts. We queried with “BMP5” in ONCOMINE using the 
default threshold parameters (p-value: 1 × 10−4, fold change: 2, and Gene rank: 10%). In our study, 
total 436 unique analysis was reported by the ONCOMINE database among which 39 studies ranked 
BMP5 within the top 10% showing significant (p < 0.05) statistical differences. Our obtained results 
revealed that BMP5 expression was down-regulated in bladder, breast, colorectal, gastric, kidney, 
lung, ovarian, prostate cancer and sarcoma compared to the expression level in normal cases (Figure 
1A) whereas up-regulation was only found to be in the central nervous system (CNS) cancer. We 
used the U133 platform of GENT database to obtain expression data of various cancer types 
compared to their normal counterparts by utilizing the microarray data profiled by Affymetrix 
platforms (see Supplementary Table S1). Herein, the results showed that BMP5 expression was 
down-regulated in several cancer types including bladder, brain, breast, colon, kidney, liver, lung, 
ovary, pancreas, prostate, stomach, testis, and thyroid (Figure 1B). In contrast, up-regulation of BMP5 
was only reported in blood, head-neck, and skin cancer. According to the analysis using the GENT 
database, the average expression of BMP5 was lower in cancer tissues than in the normal tissues. 
More to that, the analysis with the ONCOMINE and GENT database have shown that BMP5 
expression was apparently down-regulated in multiple cancer types, which includes bladder, breast, 
colorectal, lung, and ovary cancers. Therefore, we chose these respective cancer types (bladder, 
breast, colorectal, lung, and ovarian) for further systematic expression, prognosis, mutation, copy 
number alteration and protein–protein interaction analysis. 
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Figure 1: Bone morphogenetic protein 5 (BMP5) transcription level in different types of cancer derived 
from the ONCOMINE and Gene Expression across Normal and Tumor Tissue (GENT) databases. (A) 
This graphic was generated from the ONCOMINE database, indicating the number of datasets with 
statistically significant (p < 0.01) mRNA overexpression (red) or down-regulation (blue) of BMP5 
(different types of cancer vs. corresponding normal tissue). The threshold was designed with the 
following parameters: p-value of 1 × 10−4, fold change of 2, and gene ranking of 10%. (B) BMP5 mRNA 
expression pattern in normal and tumor tissues. BMP5 mRNA expression in various types of cancer 
was obtained from the GENT database. X-axis exhibits log2 fold change values of BMP5 expression 
whereas, Y-axis shows the types of tissues BMP5 were expressed. Boxes represent the median and the 
25th, and 75th percentiles dots represent outliers. Red boxes represent tumor tissues; blue boxes 
represent normal tissues. Red and blue dashed lines represent the average value of all tumor and 
normal tissues, respectively. 
3.2. Expression Pattern of BMP5 mRNA in Different Cancer Types 
We conducted cDNA microarray analysis by using the ONCOMINE database to explore the 
gene expression of BMP5 in cancer types. The ONCOMINE database was queried for BMP5 
expression in cancer and normal tissues. Our analysis revealed that BMP5 was down-regulated in 
breast, coloretal, lung, bladder and ovarian cancers, but was over-expressed only in brain and CNS 
cancers as compared to that in normal tissue (Figure 2A–F and Supplementary Table S1) [37–52]. 
Analysis of TCGA datasets through UALCAN and GEPIA database also exhibited similar BMP5 
expression in breast carcinomas, colorectal adenocarcinomas, lung squamous cell and 
adenocarcinomas, bladder cancer and glioblastomas (Figure 2G-O). Furthermore, the forest plot 
obtained from our statistical analysis shows an overall fold change pattern of BMP5 expression in six 
different cancer types reported in Supplementary Table S2 (Figure 2P). Since the expression status of  
BMP5 was confirmed in multiple databases, these results can be considered reliable. 
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Figure 2. Expression pattern of BMP5was compared between cancer and tissue. (A–F) Fold-change of 
BMP5 in six types of cancers was obtained from our analyses, shown as a box plot. The box plot 
comparing specific BMP5 expression in normal (left plot) and cancer tissue (right plot) was derived 
from the ONCOMINE database. The above and below asterisk of the box represent maximum and 
minimum value, respectively. (G–K) BMP5 expression data obtained from the TCGA database 
through GEPIA. The expression of BMP5 in lung adenocarcinoma (LUAD) and lung squamous cell 
carcinoma (LUSC) were compared and profiled against normal lung tissue samples (see I). (L–O) 
BMP5 gene expression in TCGA database. Box plots exhibiting the BMP5 mRNA expression in the 
primary tumor (red plot), respectively and their normal (blue plot) tissues, using data from the TCGA 
database through UALCAN. *: p < 0.01. (P) The fold-change of BMP5 in various types of cancers were 
compared in our analyses, as shown in Supplementary Table S1 and expressed as a bar plot. 
3.3. Prognosis Analysis of BMP5 mRNA Expression in Cancer Patients 
We summarized the prognostic value of BMP5 mRNA expression in various cancers by using 
the patient prognosis data from databases with significant Cox p-values (p <0.05). We used the 
PrognoScan database to analyze the association of BMP5 expression with survival ratio of brain and 
CNS, breast, colorectal, lung and ovarian cancer patients. In breast cancer, GSE19615 and GSE12276 
datasets showed that patients with lower BMP5 expression (n = 13 and 43, respectively) had 
significantly lower overall survival compared to patients with higher BMP5 expression (n= 102 and 
161, respectively) (Figure 3A,B; and Supplementary Table S3). Similar results were also obtained in 
colorectal cancer datasets (Figure 3C–G; and Supplementary Table S3). In Figure 3C and (E–G) the 
GSE17536 and GSE17333 datasets exhibited that the patient group with low level of BMP5 mRNA 
expression (n= 93, 101, 118 and 146, respectively) reported significantly poor overall survival 
compared to the high expression group (n= 84, 76, 108 and 31, respectively), whereas one alteration 
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reported by dataset GSE17537 contradicted the association of BMP5 low expression with overall 
survival of colorectal cancer patients (Figure 3D). Analysis of GSE31210 and Jacob-00182-MSK 
datasets of PrognoScan showed significantly (p-value) lower survival of lung cancer patients in the 
low BMP5 mRNA expression group (n= 35, 42, 12, 39 and 24, respectively) compared to their higher 
expression counterparts (n= 169, 162, 92, 65 and 180, respectively; Figure 3H-3L and Supplementary 
Table S3). High survival ratio was exhibited in low BMP5 expression group (n= 70 and 90, 
respectively) of ovarian cancer compared to the high expression group (n= 63 and 43, respectively), 
according to the DUKE-OC dataset (Figure 3M,N and Supplementary Table S3). PROGgene V2 
database was used to determine the prognosis of BMP5 expression with bladder cancer (Figure 2O). 
In GSE31684 dataset, relapse-free survival was significantly low in bladder cancer patients with the 
low expression level of BMP5 compared to their higher expression counterparts (Cox p-value: 
0.0222747). These overall data-driven results suggest that apart from one alteration in colorectal 
cancer, low expression of BMP5 is associated with poor prognosis in breast, colorectal, lung and 
bladder cancer. But in ovarian cancer, low expression of BMP5 is positively correlated with overall 
survival. Prognostic analysis on the brain and CNS cancer, however, did not show any significant 
correlation between BMP5 expression and overall patient survival.  
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Figure 3. Relationship between BMP5 expression and prognosis in various cancer patients. The 
survival curve comparing patients with high (red) and low (blue) expression in breast cancer (A–B), 
colorectal cancer (C–G), lung cancer (H–L), ovarian cancer (M–N) were retrieved from the 
PrognoScan Database. (O) Comparison of high (red) and low (green) BMP5 expression in bladder 
cancer patients plotted from the PROGgene V2 database. Survival curve analysis was conducted 
using a threshold Cox p-value < 0.05. The dotted lines represent maximum and minimum values of 
the survival average. 
In Figure 4, we summarized the prognostic value of BMP5 expression in various cancers using 
patient prognosis data from numerous databases with significant Cox p-values (p < 0.05). Moreover, 
the Kaplan Meier-plot and PrognoScan showed that low expression of BMP5 is associated with poor 
prognosis in bladder, breast, lung, and colorectal cancer compared to the prognosis in ovarian cancer 
(Figure 3). 
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Figure 4. BMP5 genes in different cancer types (PrognoScan database). The statistically significant 
hazard ratio for various kinds of cancers was identified from our analyses in Supplementary Table S2 
and expressed as the forest plot. The study of survival curve was identified as the threshold of cox p-
value < 0.05. 
3.4. Analysis of BMP5 Mutations, Copy Number Alterations and Expression of Mutant mRNA 
Genetic alterations of BMP5 in different cancer were studied by utilizing the cBioPortal database. 
The database queried for the BMP5 gene mutations in 15,405 number of samples from 26 cancer 
studies of breast, colorectal, lung, bladder, and ovarian cancer. The gene set or pathway was altered 
in 2% of the queried samples, with a somatic mutation frequency of 0.9%. In total, 146 mutations, 
including 70 duplications, were detected in patients with multiple samples (Figure 5A). Mutation 
sites were located within 1 and 454 amino acids of BMP5 propeptide and BMP5 domain. Among 
these mutations, 113 missense mutations, 29 truncating mutations and four other types of mutations 
were reported. Highest mutations were reported in breast invasive ductal and colorectal carcinoma 
and occurred in a hotspot in R321*/Q. Total fourmutations were reported in R321*/Q site, among 
which missense mutations were found in total 5397 breast invasive ductal carcinoma samples 
whereas, 837 samples of colorectal adenocarcinoma showed nonsense mutation (Table 1). Total 3 
cases of mutation were reported in the hotspot V5A/L/S in lung squamous carcinoma datasets (Figure 
5A). Alteration frequency was found highest in lung squamous carcinoma samples (>4%) among five 
cancer types (Figure 5B). Next, we generated BMP5 mRNA expression (RNA Seq V2) in 26 cancer 
studies from the cBioPortal web (Figure 5C). Highest mutated mRNA expression was profiled in lung 
cancer (36 cases) followed by bladder cancers (14 cases). Mutated BMP5 proteins were profiled in 11 
cases of breast and colorectal cancers, whereas only a single missense mutation was reported in 
ovarian cancer. 
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Figure 5. Frequency of mutations, copy number alterations (CNAs) and expression in various types 
of cancer derived from cBioPortal web. (A, B), Total 146 mutations were located within amino acids 
1 to 454 of BMP5. Highest mutations occurred in colorectal cancer, invasive breast cancer at R321*/Q 
amino acid (total 4 cases) followed by lung squamous carcinoma at V5A/L/S amino acid (total 3 cases). 
Mutation sites were located in a hotspot in BMP5-propeptide and BMP5 domain. The highest 
alteration frequency was reported in lung squamous carcinoma datasets. Only datasets containing 
>100 samples per cancer types are shown. The alteration frequency exhibited mutations (green), 
fusions (violet) and multiple alterations (grey). (C) BMP5 mRNA expression (RNA Seq V2) in 24 
cancer studies generated from the cBioPortal web. Mutations were reported in bladder cancer, breast 
cancer, colorectal cancer, lung cancer and ovarian cancer. Highest mutated mRNA expression 
occurred in lung cancer (36 cases). The x-axis is divided according to the cancer types, and Y-axis 
represents BMP5 mRNA expression levels. The expression frequency exhibited missense mutations 
(green), fusions (violet), truncating (deep blue), no mutations (blue), and no profiled mutations 
(white). 





































R321* Nonsense 144 TCGA-D5-6533-01 
Total of five mutations reported in amino acid R321 in breast cancer and colorectal cancer datasets. 
Total 10,507 mutations were reported in five samples. 
3.5. Prediction of Protein–Protein Interaction and Cross-Cancer Analysis of BMP5 Mutations and Copy 
Number Alterations 
We found the protein–protein interactions (PPI) involving BMP5 by using GeneMANIA and 
STRING web, which compiles data on co-expression, co-localization, genetic interactions, pathways 
involved, physical interaction predictions and shared protein domains. The predicted protein 
partners of BMP5 were: HJV (HFE2-hemochromatosis type 2 juvenile), TBX5 (T-box 5), SOST 
(sclerostin), LRP5 (LDL receptor related protein 5), RGMA (repulsive guidance molecule family 
member a), RGMB (repulsive guidance molecule family member b), BMP2 (bone morphogenetic 
protein 2), BMP4 (bone morphogenetic protein 4), BMP7 (bone morphogenetic protein 7), BMP10 
(bone morphogenetic protein 10), FST (follistatin), CHRDL2 (chordin-like 2), GLI1 (GLI family zinc 
finger 1), BAMBI (BMP and activin membrane bound inhibitor), NOG (noggin), CHRD (chordin), 
NKX2-5 (NK2 homeobox 5), IL1RL1 (interleukin 1 receptor like 1), GATA4 (GATA binding protein 4), 
TGFB2 (transforming growth factor beta 2), EDNRB (endothelin receptor type B), BMPR1A (bone 
morphogenetic protein receptor type 1A), FKBP1A (FK506 binding protein 1A), AMHR2 (anti-
mullerian hormone receptor type 2), ACVR1 (activin A receptor type 1), ACVRL1 (activin A receptor 
like type 1), ACVR1B (activin A receptor type 1B), ACVR2A (activin A receptor type 2A), ACVR2B 
(activin A receptor type 2B) and ACVR1C (activin A receptor type 1C) (Figure 6A-6B). Thus, these 
predicted interacting protein partners of BMP5 might be involved in the regulation of BMP5-
mediated cancer progression and prognosis. 
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Figure 6. Interaction and co-occurrence functional protein partners of BMP5. (A,B) Predicted 
structural proteins essential for the functioning of BMP5 generated from GeneMANIA and STRING 
web. Circles displayed are indicating nodes. Predicted functional partners are shown after 
considering co-expression, co-localization, genetic interactions, pathways, physical interactions and 
predicted shared protein domains. (C) The alteration frequency of 31 gene signature from 
GeneMANIA database (BMP5, HJV(HFE2), TBX5, SOST, LRP5, RGMA, RGMB, BMP2, BMP4, BMP7, 
BMP10, FST, CHRDL2, GLI1, BAMBI, NOG, CHRD, NKX2-5, IL1RL1, GATA4, TGFB2, EDNRB, 
BMPR1A, FKBP1A, AMHR2, ACVR1, ACVRL1, ACVR1B, ACVR2A, ACVR2B, ACVR1C) was 
determined using cBioPortal web. Datasets containing > 100 samples per cancer type and alteration 
frequency of >20% are shown. Highest alterations were reported in lung squamous carcinoma 
datasets (>60%). The alteration frequency included mutations (green), fusions (violet), amplifications 
(red), deep deletions (deep blue) and multiple alterations (grey). 
We also analyzed the mutations and copy number alterations (CNAs) in the 30 predicted 
interacting protein partners of BMP5 by using the ONCOPRINT feature of cBioPortal database. 
Queried genes were altered in 6751 (38%) of queried patients in 6825 (37%) of queried samples. 
Highest alteration frequency was found in lung squamous carcinoma (>60%) whereas, colorectal 
cancer exhibited the lowest alteration (<40%) among all of the query cancer samples (Figure 6C). 
Among the 30 datasets containing above 100 patient samples, CHRD showed the highest alteration 
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frequency (8%) followed by HEF-2 and TGFB2 (6%) whereas, SOST exhibited the lowest frequency 
(0.8%) in CNA (Figure S1). The percentage of alteration frequency varied from 0.8–8.0% for individual 
genes. 
3.6. Co-occurrence Analysis of Functional Protein Partners of BMP5 in Cancers 
We determined the correlation significance of the functional protein partners of BMP5 by using 
the co-occurrence analysis sub-tool of cBioPortal, which is based on Fisher′s exact test. In total, 11 
genes reported significant co-occurrence of alteration associated with BMP5 (Table 2). All the genes 
exhibited p-value of < 0.001 and log odds ratio (LOR) of > 1. 
Table 2. Mutual exclusivity analysis reporting co-occurrence of alterations in the BMP5 gene 
signature was investigated using cBioPortal for Cancer Genomics. 
Co-occurrence Gene p-Value Log Odds Ratio Tendency Significance 
CHRD <0.001 2.139 Co-occurrence Significant 
GLI1 <0.001 2.153 Co-occurrence Significant 
IL1RL1 <0.001 2.392 Co-occurrence Significant 
TGFB2 <0.001 2.136 Co-occurrence Significant 
BAMBI <0.001 2.138 Co-occurrence Significant 
ACVR2A <0.001 2.046 Co-occurrence Significant 
ACVR1C <0.001 2.350 Co-occurrence Significant 
HJV(HFE2) <0.001 1.866 Co-occurrence Significant 
ACVR1 <0.001 2.250 Co-occurrence Significant 
AMHR2 <0.001 2.208 Co-occurrence Significant 
EDNRB <0.001 1.504 Co-occurrence Significant 
Total 30 cancer datasets containing samples for five cancer types were investigated. Significant co-
occurrence was reported only for the pairs resulting with p < 0.001. 
3.7. Co-expression Heatmap of Functional Protein Partners of BMP5 in Cancers 
We visualized the global features of our gene co-expression data of BMP5 functional protein 
partners by conducting hierarchical clustering (Figure 7, Supplementary Table S4). 
Hierarchical clustering of expression fold-change values of BMP5 and 11 functional protein 
partners in 6 different cancers provides an overview of functional correlation. The analysis showed 
that BMP5 was significantly co-expressed with ACVR1C in mixed lobular and ductal breast, invasive 
lobular breast, colon, rectal mucinous, cecum mucinous and rectum adenocarcinoma. BAMBI, on the 
other hand, showed weak co-expression in colon adenocarcinoma and ovarian serous surface 
papillary carcinoma. GLI1 showed a significant level of co-expression in mucinous breast carcinoma 
and ovarian serous surface papillary carcinoma, whereas AMHR2, CHRD, and ACVR2A showed a 
similar pattern in ovarian serous papillary carcinoma, superficial bladder carcinoma and infiltrating 
urothelial bladder carcinoma. IL1RL1 exhibited similar down-regulation in large cell lung carcinoma 
and lung adenocarcinoma. In contrast, IL1RL1, TGFB2, GLI1, and EDNRB was over-expressed in 
classical, and desmoplastic medulloblastoma, and glioblastoma. 
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Figure 7. A heatmap visualizing co-expression profile of BMP5 in breast, colorectal, lung, bladder, 
ovarian carcinoma and blastoma. BMP5 is co-expressed with the indicated genes across 3 lung, 7 
breast, 8 colorectal, 3 blastoma, 2 bladder, and 1 ovarian cancer sample types. Linear branches on the 
left and top are clustering tree grouping similar expression pattern of BMP5 gene in different cancer 
types. The color scale indicates the expression value (Dark blue indicate higher expression, red 
indicates lower gene expression). The heat map was generated with custom scripts based on 
pheatmap function as available in the ‘gplots’ Bioconductor package of R. 
3.8. Differentially Expressed Genes with BMP5 Expression in Five Types of Cancers and Their Function 
We aimed to find the potential signalling mechanism involved with BMP5 expression in cancers. 
To investigate the BMP5-related pathways that might commonly play a role in various cancers, we 
analyzed transcriptome datasets from five different types of cancers, namely, breast, colon,lung, 
bladder, and ovarian cancer using TCGA and RSEM datasets through the R2: Genomics Analysis and 
Visualization Platform. Forty differently expressed genes (DEGs) were commonly up-regulated with 
BMP5 in five selected cancers derived from the Venn diagram (Figure 8A). 
In our query, a total of 2709 genes were commonly found to be differentially expressed in at least 
three out of five cancer types. Later we queried for the 11 significantly co-occurrent genes found in 
previous analysis (Table 2). In our query, EDNRB is shown to be co-expressed with BMP5 in bladder, 
breast, colorectal and lung cancer. ACVR2A, ACVR1C, BMP4, and CHRDL2, on the other hand, was 
found to be commonly co-expressed with BMP5 in bladder, breast and lung cancer. GLI1 also shown 
co-expression within breast, lung and ovarian cancer datasets. CHRD, NKX2-5 were also co-
expressed in bladder and ovarian cancer datasets whereas BAMBI was only reported in breast and 
lung datasets. Next, the common Down-regulated DEGs obtained from R2 and cBioPortal co-
occurrence was classified using PANTHER pathway analysis (Figure 8B and Figure S2) and the 
GOnet: Gene Ontology Analysis tool (Supplementary Table S5). BMP5 correlated gene cluster 
affected 33 pathways and was involved in diverse roles such as; TGF-beta signalling pathway, 
Gonadotropin releasing hormone receptor pathway, EGF-receptor and EGF signalling pathway. We 
showed that cellular process, cell proliferation and metabolic process are the main biological 
functions associated with BMP5 (Figure S2A). In addition, binding and catalytic activities were the 
main molecular function associated with BMP5 (Figure S2B). Cell, membrane and protein-containing 
complex were the major three cellular components associated with BMP5 gene clusters. Categories 
obtained from analysis using GOnet: Gene Ontology Analysis tool also contains terms related to 
signal transduction, gene expression regulation along with cellular proliferation and differentiation, 
metabolic process regulation, transcriptional and translational regulation and system development 
(Supplementary Table S5). As conveyed by these results, BMP5 could be associated with certain key 
signaling pathways related to cellular proliferation, differentiation, metabolism and post-
transcriptional control corresponding to cancer progression. 
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Figure 8. Analysis of genes that positively correlated with BMP5 and their pathways. (A) Analysis of 
positively correlated genes of BMP5 using the R2: Genomics Analysis and Visualization Platform. 
Venn diagram of genes positively correlated to BMP5, showing coincident genes in breast, colorectal, 
lung, bladder, and ovarian cancers. (B) Pathway analysis of BMP5 using PANTHER and subsequent 
classification based on their pathways; p < 0.05. 
We want to draw attention to the possibility of eventually being able to derive signaling 
pathways based on PPI analysis. In our study, the gene list attained by using R2 is characteristically 
different from the gene list found from PPI investigation. R2 analysis represents the co-expression 
whereas the latter symbolizes the physical network. On one hand, the correlated genes are pair of 
genes that shows a similar expression pattern across samples, since the level of transcription of two 
co-expressed genes rises and fall together across samples. Networks of gene co-expression are of 
biological interest since co-expressed genes are controlled by the same transcriptional regulatory 
mechanism, functionally related, or members of the same pathway or protein complex. On the other 
hand, PPIs are the physical contacts of high specificity established between two or more protein 
molecules as a result of biochemical events stimulated by electrostatic forces that include 
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hydrophobic effects. On that, we have used the PPI and list of correlated genes for two different 
purposes. Since genetic alterations are a type of inherent physical manipulation, we used PPI to 
investigate mutations and CNAs in our query genes. In contrast, we used correlated genes to gain 
some insights into the signaling pathways. 
4. Discussion 
BMP5 is a member of TGF-β superfamily and is known to play a regulatory role in the metastasis 
of lung, thymus, bone marrow, spleen, skeletal muscle, heart, kidney, pancreas, and prostate tissues 
[53]. It is involved in multivariate disease development and suppression process. It was found in 
various cases of cancers including breast cancer [20], lung cancer [17], colorectal cancer [12], ovarian 
cancer [54], bladder cancer [55], skin cancer [56], etc. The mRNA level of BMP5 was higher in female 
than the male counterparts in non-small-cell lung cancer (NSCLC) [17]. The overexpressed BMP5 
mRNA has also been found in the squamous cell carcinoma. Conversely, down-regulation was 
detected in adrenocortical carcinoma cells [9,57]. It plays a role as a tumor suppressor in myeloma, 
adrenocortical carcinoma, and breast cancer [20,58]. BMP5 inhibits the proliferation and promote 
migration and invasion of pancreatic cancer cell and thus exhibit a biphasic role [59]. 
We transact a multi-omics analysis to understand the potency of BMP5 as an oncogene or 
prognostic marker gene in different cancers. To determine the role of BMP5 in cancer, we have 
explicitly evaluated the expression pattern of genes in the cancers. normal tissues by using defined 
parameters through computational analysis. In ONCOMINE and GENT database analysis, we found 
differential expression pattern depending on cancer cell types. The BMP5 gene expression in breast, 
bladder, colorectal, lung and ovarian cancer cells was found lower in compared to normal cells, 
whereas, it was higher in the brain and CNS cancer. Then we performed distinct analysis for revealing 
the role of BMP5 in breast, bladder, colorectal, lung, and ovarian cancers. In the case of breast cancer, 
BMP5 expression was low using ONCOMINE, UALCAN, and GEPIA database. Our further 
expression analysis using these analyzing tools exhibited similar results for bladder, colorectal, lung, 
and ovarian cancers. This results also support the previous results where Deng et al. reported lower 
BMP5 expression in NSCLC tissues by quantitative real-time PCR analysis [17]. 
Overall, our analysis has shown that BMP5 was significantly down-regulated in several cancer 
datasets. However, we were unable to identify a consistent clinical outcome pattern relating to the 
clusters. It is important to note that the survival data of several TCGA data set are limited by the 
length of follow up [60,61]. 
To understand the role of BMP5 in cancer more definitely, we investigated the prognostic status 
of BMP5 in breast, bladder, colorectal, lung, and ovarian cancer. We utilized the PrognoScan database 
to find out the association of BMP5 mRNA expression and overall survival rate. The inquisition 
reports that lower BMP5 mRNA expression was associated with lower overall survival rate in breast 
cancer and lung cancer. In breast cancer, Blimp-1 plays an inevitable role in TGF-β1 mediated 
epithelial-to-mesenchymal transition (EMT) through the suppression of BMP5 expression [20]. In 
colorectal cancer due to the conflicting results, the role of BMP5 in colorectal cancer was not clear. 
According to the study of William et al. BMP5 inuced ERBB4 is over-expressed in human CRC, and 
in experimental systems enhances the survival and growth of cells driven by Ras and/or WNT 
signaling. Chronic ERBB4 over-expression in the context of, for example, inflammation may 
contribute to the development of colorectal cancer [62]. Results exhibited an association of lower 
expression with lower survival rate from four survival curve analysis (Figure 3C,E–G), whereas 
another one exhibited the opposite result (Figure 3E). Chen et al. observed the down-regulation of 
BMP5 in colorectal cancer due to the miR-32 deregulation [14]. The mean results of the analysis of the 
current investigation suggest the role of BMP5 as tumor suppressor gene in colorectal cancer. This 
result also supports the previous findings, where BMP5 acts as a tumor suppressor in colorectal 
cancer [12]. Our analysis on ovarian cancer represents the correlation between lower BMP5 mRNA 
expression and higher overall survival rate. BMP2, 5 and rhBMP9 has been reported to be involved 
in RAS-MAPK mediated pathway that activates p65 cytokine and during tumorigenesis and thus 
proliferate ovarian cancer [63,64]. On the other hand, investigation on bladder cancer prognosis 
Biomedicines 2020, 8, 19 17 of 24 
relevance using PROGgene V2 database recommends a positive relation between lower BMP5 
expression and lower relapse-free survival. This consistent trend in BMP5 expression in cancers 
suggests a commonality among different cancer types, where BMP5-related molecular pathways may 
be functional. 
Cancer progression is a series of histopathological process, which is influenced by somatically 
acquired genetic, epigenetic, transcriptomic and proteomic alterations [65–67]. Somatic loss-of-
function or gain-of-function alterations ensue in particular genomic regions which engaged in 
potential inhibitory or carcinogenic effects, respectively [68,69]. Therefore, we exploited the 
cBioPortal web tool to exhibit the Copy Number Alterations, mutations and mutant mRNA 
expressions. Missense and truncating mutations pre-eminently occurred within protein-coding 
sequences [13]. Ho et al. reported a novel missense mutation in BMP5 transcript with a G-to-A 
substitution in RXXR cleavage consensus site. The G-to-A mutation at nucleotide 932 cleaves the 
nucleotides encoding arginine (CGA) residue and thus destroys the Taq I polymerase restriction site 
resulting in the blockage of the post-translational processing of the BMP5 protein [70]. In our analysis, 
we found diverse missense and truncating mutations in the BMP5 protein-coding sequence while 
exposed to cancer cells. This study revealed mutations in breast invasive ductal and colorectal 
carcinoma in a hotspot at position R321*/Q and position V5A/L/S in lung squamous carcinoma 
between BMP5-propeptide and BMP5 domain. Similar results of mutation at R321*/Q stop-codon (4 
cases) was also found in a previous study which may impact cleavage of the protein to the mature 
secreted form [13]. Highest alteration frequency was obtained from lung squamous carcinoma. 
Another BMP5 mRNA expression (RNA Seq V2) analysis via cBioPortal web found a higher mutation 
rate in lung cancer and then in bladder cancers. These mutations may have played an essential role 
in cancer progression and prognosis. 
It has been reported that PPI is associated with various biological processes, such as signal 
transduction and disease development [71]. To predict their functional protein partner, we exploited 
GeneMANIA and STRING web server. These interacted proteins have a role in the regulation of 
tumor progression. A total of 30 proteins were determined as protein partners, and these interacting 
proteins were used to detect copy number alterations and mutations through the cBioPortal tool. 
From the lowest to the highest dominance hierarchy, the ratio of alteration ranged over >25% to >60%. 
The copy number alteration frequency of each gene showed that CHRD obtains the highest alteration 
frequency with a percentage of 8% whereas SOST occupied the lowest position. After that, the 
correlation between each gene and BMP5 was evaluated significantly via cBioPortal under specific 
parameter. This analysis reports the co-occurrence genes association with BMP5 during 
tumorigenesis. To determine the hierarchy, we also observed a heatmap characterized by fold-change 
values of the 11 functional partners of BMP5. GLI1 and ACVR1C were found to be down-regulated 
in breast, colorectal, and ovarian cancer. Previous reports also suggest that both GLI1 and ACVR1C 
are down-regulated in breast cancer [72]. ACVR1C down-regulation in colorectal cancer was reported 
in several studies [73,74]. However, previous studies reported that GLI1 overexpression in malignant 
ovarian epithelial tumor enables tumor metastasis and increase risk in ovarian cancer patient [75,76]. 
These reports are not similar to our findings in Figure 7 and Table 1 of S2 File. Previous studies found 
that BAMBI regulates CRC and NSCLC metastasis by connecting the Wnt/beta-catenin and TGF-β-
signalling pathways which validate our findings [77,78]. BAMBI is also reported to be overexpressed 
in breast and ovarian cancer and co-translocate with Smads into the nucleus upon TGF-β treatment 
[79,80]. Circular ACVR2A expression was found to be suppressed in bladder cancer tissues and cell 
lines and has a functional role in bladder cancer inhibition and metastasis [81]. CHRD was found to 
be significantly under-expressed in ovarian cancer compared to normal tissues suggesting its 
potential of regulating BMP activity in normal ovarian surface epithelium physiology [82]. Several 
reports on IL1RL1 down-regulation in lung cancer also validates our findings in this study [83,84]. 
Here, our findings validate the co-expression significance of BMP5 with its predicted functional 
protein partners in several cancers. 
Finally, we determined the genes correlated with BMP5 in five types of cancer (breast, lung, 
colorectal, bladder, and ovarian) in which this TGF-β family member is significantly down-regulated 
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by using R2 platform. For BMP5, a large number of positively-correlated genes were found in breast, 
colon, lung, bladder, and ovarian cancer. Of those genes, 40 were common in all cancers along with 
2709 genes common in at least three out of five cancers. R2 analysis also validates our findings from 
cBioPortal analysis and heatmap of fold change values of the 11 protein partners. In addition, we 
used the PANTHER pathway and GOnet: Gene Ontology Analysis tool to determine the GO and 
pathways associated with these commonly correlated genes for BMP5. According to the pathway 
analysis, ACVR1C, ACVR2A, AMHR2, TGFB2, BAMBI, and BMP5 were predominantly found to be 
involved in TGF- β signalling and gonadotrophin releasing hormone receptor pathways. The co-
expression analysis shows that BMP5 expression is positively correlated with transmembrane 
receptor protein serine/threonine kinase pathway regulation, cellular proliferation and 
differentiation, metabolic process regulation, transcriptional and translational regulation, regulation 
of cell death, and system development (Supplementary Table S5). GO analysis completely validates 
our findings on co-expression and pathway regulation of functional protein partners of BMP5. 
However, their underlying mechanism in development of cancers and the effects on clinical outcomes 
remains unknown.BMP5BMP5BMP5BMP5BMP5BMP5BMP5 
5. Conclusion 
In this mining study, we used several online bioinformatics platform and web tools to 
systematically analyze the expression, mutations and CNAs, correlated genes, and prognostic value 
of BMP5 in human various cancers. The multi-omics analysis revealed that BMP5 is down-regulated 
distinctively and is negatively correlated with clinical outcomes in breast colorectal, lung, and 
bladder, except ovarian cancer. Ovarian cancer is positively correlated. The present findings also 
reveal the importance of BMP5 expression and possible BMP5-related pathways in human various 
cancers progression. Overall, our analysis may provide valuable insights into BMP5 as a novel 
biomarker and a potential therapeutic target for various human cancers and thus, will assist in 
transforming genomic knowledge into clinical practice. Hence, the specific roles, detailed molecular 
mechanisms, and clinical significance of BMP5 in cancer progression and prognosis deserve further 
investigation 
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ADC Adenocarcinoma  
C Carcinoma  
CAD Colon adenoma  
CCC Clear cell carcinoma. 
CEAD Cecum adenocarcinoma  
CMAD Cecum mucinous adenocarcinoma 
CMAD Colon mucinous adenocarcinoma 
CMBM Classical medulloblastoma 
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COAD 
Colon carcinoma  
Colon adenocarcinoma  
CRA Colorectal adenomacarcinoma 
CRAD Colorectal adenocarcinoma  
CRC Colorectal carcinoma  
DMBM Desmoplastic medulloblastoma 
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GBM Glioblastoma 
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IDBC Invasive ductal breast carcinoma  
ILBC Invasive lobular and ductal breast carcinoma  
LCLC Large cell lung carcinoma  
LUAD Lung adenocarcinoma  
LUSC Lung squamous cell carcinoma  
MC Mucinous carcinoma  
MixC Mixed carcinoma  
MLDBC Mixed lobular and ductal breast carcinoma  
MPC Micropapillary carcinoma  
MUBC Mucinous breast carcinoma  
OC Ovarian cancer 
OSAD Ovarian surface adenocarcinoma 
OSSPC Ovarian serous surface papillary carcinoma 
RAD Rectal adenocarcinoma  
READ Rectum mucinous adenocarcinoma 
RMAD Rectal mucinous adenocarcinoma 
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SBC Serous breast carcinoma  
TCGA The cancer genome atlas 
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